AI Article Synopsis
- The study investigates the relationship between nonalcoholic fatty liver disease (NAFLD) and the severity and outcomes of acute ischemic stroke in 200 patients.
- Results indicate that 42.5% of patients had NAFLD, which was associated with higher rates of diabetes and elevated levels of glucose, triglycerides, and liver enzymes compared to those without NAFLD.
- Findings suggest that patients with NAFLD experienced more severe strokes and poorer recovery outcomes, highlighting the potential risks linked to NAFLD in stroke patients.
Article Abstract
Background: There is a paucity of data regarding the association between nonalcoholic fatty liver disease (NAFLD) and acute ischemic stroke. Stroke is largely preventable, so that knowledge of risk factors is essential to achieve reductions in the stroke rate and resulting disease burden.
Objective: The aim of the present study was to evaluate the prognostic value of NAFLD on stroke severity and outcome.
Methods: We prospectively studied 200 patients who were admitted with acute ischemic stroke between September 2013 and August 2015. Demographic and vascular risk factors were detailed for all subjects. The severity of stroke was assessed with National Institutes of Health Stroke Scale score at admission. NAFLD was defined as serum alanine aminotransferase and/or aspartate aminotransferase levels above the upper limit of normal in the absence of other causes of elevated aminotransferase levels. The outcome was assessed with the modified Rankin scale score at discharge.
Results: NAFLD was found in 42.5% of the study population. The prevalence of diabetes was significantly higher among patients with NAFLD than those without NAFLD (P = .001). Waist circumference was significantly higher among patients with NAFLD than those without NAFLD (P < .05). Patients with NAFLD had significantly higher glucose, Triglycerides, Low density lipoprotein, serum alanine aminotransferase and aspartate aminotransferase than those without NAFLD (P < .05 for each comparison). National Institutes of Health Stroke Scale score at admission and modified Rankin scale score at discharge were significantly higher in patients with NAFLD than those without NAFLD (P < .05 for each comparison).
Conclusion: NAFLD was found in 42.5% of acute ischemic stroke patients. NAFLD might be associated with more severe stroke and worse outcome.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacl.2017.04.115 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
L-carnitine attenuates autophagic flux, apoptosis, and necroptosis in rats with dexamethasone-induced non-alcoholic steatohepatitis.
BMC Pharmacol Toxicol
December 2024
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt.
Background: UpToDate, no drugs have been approved to treat nonalcoholic steatohepatitis, the advanced stage of the most prevalent liver disease, non-alcoholic fatty liver disease. The present study was conducted to explore the potential influences of L-carnitine on the pathomechanisms of hepatic injury that mediate progression to non-alcoholic steatohepatitis in dexamethasone-toxified rats.
Methods: Male Wistar rats were allocated as follows: dexamethasone group, rats received dexamethasone (8 mg/kg/day, intraperitoneally) for 6 days; DEXA-LCAR300, DEXA-LCAR500, and DEXA-MET groups, rats administered L-carnitine (300 or 500 mg/kg/day, IP) or metformin (500 mg/kg/day, orally) one week prior to dexamethasone injection (8 mg/kg/day, IP) and other six days alongside dexamethasone administration.
Cognitive Impairment in MASLD is associated with Amygdala-Related Connectivity Dysfunction in the Prefrontal and Sensory Cortex.
J Integr Neurosci
December 2024
Department of Radiology, The Affiliated Hospital of Hangzhou Normal University, 310015 Hangzhou, Zhejiang, China.
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common metabolism-related multisystem clinical disorder, often accompanied by a high comorbidity of mild cognitive impairment (MCI). Increasing evidence suggests that the amygdala is crucial in cognitive processing during metabolic dysfunction. Nevertheless, the role of the amygdala in the neural mechanisms of MASLD with MCI (MCI_MASLD) remains unclear.
View Article and Find Full Text PDFGLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis.
World J Gastroenterol
December 2024
Department of Cardiology, Dayanand Medical College and Hospital, Ludhiana 141001, Punjab, India.
The global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is estimated at 32.4%, reflecting its growing clinical significance. MASLD, which includes MASLD and metabolic dysfunction-associated steatohepatitis (MASH) has been linked to increased metabolic, cardiovascular, and malignant morbidity.
View Article and Find Full Text PDFChild-Pugh Score and Vitamin D: Exploring a New Frontier in Liver Cirrhosis Assessment.
Cureus
November 2024
Medicine, Shri. B. M. Patil Medical College Hospital and Research Centre, Vijayapura, IND.
This study investigates the relationship between vitamin D levels and liver cirrhosis severity, a leading cause of global morbidity and mortality. Chronic liver diseases, stemming from conditions such as hepatitis, alcohol use, non-alcoholic fatty liver disease, autoimmune diseases, and cryptogenic disorders, disrupt vitamin D metabolism, as the liver converts dietary and skin-derived vitamin D into 25-hydroxyvitamin D (25[OH]D), the primary circulating form. The cross-sectional study conducted at the Department of General Medicine of BLDE (DU) Shri.
View Article and Find Full Text PDFResmetirom in the Management of Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Comprehensive Review of Current Evidence and Therapeutic Potential.
Cureus
November 2024
Gastroenterology, University of Rochester, Rochester, USA.
Resmetirom is a thyroid hormone receptor agonist that has been recently approved by the FDA for the management of metabolic dysfunction-associated steatohepatitis (MASH). MASH is a severe form of metabolic dysfunction-associated fatty liver disease (MASLD), which is marked by hepatic inflammation and potential progression to cirrhosis and liver cancer. This review analyzes and demonstrates the efficacy of resmetirom in reducing intra-hepatic lipids, improving liver histology, and improving metabolic parameters.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!